Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783172339> ?p ?o ?g. }
- W2783172339 endingPage "2134" @default.
- W2783172339 startingPage "2128" @default.
- W2783172339 abstract "In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with low-grade NHL. The regimen included rituximab on day 1 with weekly cyclophosphamide, dexamethasone, and bortezomib 1.3 mg/m2 IV in a 28-day cycle. Twenty one patients were enrolled on the study. Median age was 69 years (range 51-80) and 17 (81%) patients had two or more prior treatments. Histologies included FL (n = 8), MCL (n = 8), and LPL/WM (n = 5). Hematologic toxicity and peripheral sensory neuropathy were the most common adverse events. With a median follow-up of 38.1 months, ORR was 13/21 (62%), with 4 (19%) CR. The ORR was 7/8 (88%) in FL and was 4/5 (80%) in LPL/WM. Median PFS and OS were 11.6 months and 54.8 months, respectively. R-CyBorD is an effective regimen in relapsed FL and LPL/WM patients with an acceptable safety profile." @default.
- W2783172339 created "2018-01-26" @default.
- W2783172339 creator A5000432344 @default.
- W2783172339 creator A5004152557 @default.
- W2783172339 creator A5004436275 @default.
- W2783172339 creator A5025688165 @default.
- W2783172339 creator A5027394636 @default.
- W2783172339 creator A5038693643 @default.
- W2783172339 creator A5046797169 @default.
- W2783172339 creator A5048646563 @default.
- W2783172339 creator A5050306435 @default.
- W2783172339 creator A5051399808 @default.
- W2783172339 creator A5059366804 @default.
- W2783172339 creator A5059729547 @default.
- W2783172339 creator A5070784780 @default.
- W2783172339 creator A5071201232 @default.
- W2783172339 creator A5076892547 @default.
- W2783172339 creator A5083820701 @default.
- W2783172339 creator A5087950597 @default.
- W2783172339 creator A5090009905 @default.
- W2783172339 date "2018-01-10" @default.
- W2783172339 modified "2023-09-28" @default.
- W2783172339 title "A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma" @default.
- W2783172339 cites W1980168719 @default.
- W2783172339 cites W1985343909 @default.
- W2783172339 cites W2012098025 @default.
- W2783172339 cites W2015003025 @default.
- W2783172339 cites W2073942227 @default.
- W2783172339 cites W2091319225 @default.
- W2783172339 cites W2100608938 @default.
- W2783172339 cites W2116895103 @default.
- W2783172339 cites W2119680582 @default.
- W2783172339 cites W2120755425 @default.
- W2783172339 cites W2127749132 @default.
- W2783172339 cites W2131998596 @default.
- W2783172339 cites W2133201432 @default.
- W2783172339 cites W2134861285 @default.
- W2783172339 cites W2135321054 @default.
- W2783172339 cites W2138404218 @default.
- W2783172339 cites W2147422161 @default.
- W2783172339 cites W2150280279 @default.
- W2783172339 cites W2154643481 @default.
- W2783172339 cites W2156522119 @default.
- W2783172339 cites W2160093471 @default.
- W2783172339 cites W2167355583 @default.
- W2783172339 cites W2169183166 @default.
- W2783172339 cites W2169209759 @default.
- W2783172339 cites W2170362988 @default.
- W2783172339 cites W2729141564 @default.
- W2783172339 doi "https://doi.org/10.1080/10428194.2017.1416368" @default.
- W2783172339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29320913" @default.
- W2783172339 hasPublicationYear "2018" @default.
- W2783172339 type Work @default.
- W2783172339 sameAs 2783172339 @default.
- W2783172339 citedByCount "4" @default.
- W2783172339 countsByYear W27831723392019 @default.
- W2783172339 countsByYear W27831723392020 @default.
- W2783172339 countsByYear W27831723392021 @default.
- W2783172339 countsByYear W27831723392023 @default.
- W2783172339 crossrefType "journal-article" @default.
- W2783172339 hasAuthorship W2783172339A5000432344 @default.
- W2783172339 hasAuthorship W2783172339A5004152557 @default.
- W2783172339 hasAuthorship W2783172339A5004436275 @default.
- W2783172339 hasAuthorship W2783172339A5025688165 @default.
- W2783172339 hasAuthorship W2783172339A5027394636 @default.
- W2783172339 hasAuthorship W2783172339A5038693643 @default.
- W2783172339 hasAuthorship W2783172339A5046797169 @default.
- W2783172339 hasAuthorship W2783172339A5048646563 @default.
- W2783172339 hasAuthorship W2783172339A5050306435 @default.
- W2783172339 hasAuthorship W2783172339A5051399808 @default.
- W2783172339 hasAuthorship W2783172339A5059366804 @default.
- W2783172339 hasAuthorship W2783172339A5059729547 @default.
- W2783172339 hasAuthorship W2783172339A5070784780 @default.
- W2783172339 hasAuthorship W2783172339A5071201232 @default.
- W2783172339 hasAuthorship W2783172339A5076892547 @default.
- W2783172339 hasAuthorship W2783172339A5083820701 @default.
- W2783172339 hasAuthorship W2783172339A5087950597 @default.
- W2783172339 hasAuthorship W2783172339A5090009905 @default.
- W2783172339 hasConcept C126322002 @default.
- W2783172339 hasConcept C141071460 @default.
- W2783172339 hasConcept C143998085 @default.
- W2783172339 hasConcept C197934379 @default.
- W2783172339 hasConcept C2776364478 @default.
- W2783172339 hasConcept C2776694085 @default.
- W2783172339 hasConcept C2776755627 @default.
- W2783172339 hasConcept C2777478702 @default.
- W2783172339 hasConcept C2777525834 @default.
- W2783172339 hasConcept C2779338263 @default.
- W2783172339 hasConcept C2780401358 @default.
- W2783172339 hasConcept C2780653079 @default.
- W2783172339 hasConcept C2781413609 @default.
- W2783172339 hasConcept C31760486 @default.
- W2783172339 hasConcept C71924100 @default.
- W2783172339 hasConcept C90924648 @default.
- W2783172339 hasConceptScore W2783172339C126322002 @default.
- W2783172339 hasConceptScore W2783172339C141071460 @default.
- W2783172339 hasConceptScore W2783172339C143998085 @default.
- W2783172339 hasConceptScore W2783172339C197934379 @default.